Endologix Announces First U.S. Implant of AFX™ Endovascular AAA System

IRVINE, Calif., Aug. 8, 2011 /PRNewswire/ -- Endologix, Inc. (Nasdaq: ELGX), developer and marketer of minimally invasive treatments for aortic disorders, announced today that the first U.S. commercial implant of the Company's AFX™ Endovascular AAA System was performed at Edward Hines, Jr. VA Hospital in Chicago, IL. The procedure was performed by Ross Milner, M.D., F.A.C.S., Associate Professor and Chief of Vascular Surgery & Endovascular Therapy at Loyola University in Chicago, IL.

Dr. Milner commented, "We are excited to be the first hospital in the U.S. to bring the benefits of the new AFX system to a patient in our local community. The device builds on the compelling clinical evidence supporting Endologix's unique anatomical fixation technology with an enhanced, lower profile delivery system and new graft material. The 17Fr introducer sheath and integrated delivery system make it easy to use in a wide range of patient anatomies. The AFX system performed very well during the procedure; the delivery and deployment of the stent graft was quick and precise, and post-procedure imaging confirmed that the aneurysm was effectively sealed."

John McDermott, President and Chief Executive Officer of Endologix, commented, "We are pleased with the results from the initial implant and would like to thank Dr. Milner and his team for performing the procedure. We look forward to providing this exciting new endovascular device to physicians and patients in the U.S. in September."

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 75%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's Web site at www.endologix.com.

Forward-Looking Statements

Except for historical information contained herein, this news release contains forward-looking statements relating to the planned launch of the AFX system, the accuracy of which are necessarily subject to risks and uncertainties, all of which are difficult or impossible to predict accurately and many of which are beyond the control of Endologix. Many factors may cause actual results to differ materially from anticipated results, including the uncertainties related to the introduction and clinical acceptance of new products. The Company undertakes no obligation to update its forward looking statements. Please refer to the Company's Annual Report on Form 10-K for the year ended December 31, 2010, and the Company's other filings with the Securities and Exchange Commission, for more detailed information regarding these risks and other factors that may cause actual results to differ materially from those expressed or implied.

SOURCE Endologix, Inc.